Literature DB >> 2278542

Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population.

M B Edmonson1, D G Addiss, J T McPherson, J L Berg, S R Circo, J P Davis.   

Abstract

A prolonged school-based outbreak of measles provided an opportunity to study "vaccine-modified" mild measles and secondary vaccine failure. Thirty-six (97%) of 37 unvaccinated patients had rash illnesses that met the Centers for Disease Control clinical case definition of measles, but 29 (15%) of 198 vaccinated patients did not, primarily because of low-grade or absent fever. Of 122 patients with seroconfirmed measles, 10 patients (all previously vaccinated) had no detectable measles-specific IgM and significantly milder illness than either vaccinated or unvaccinated patients with IgM-positive serum. Of 108 vaccinated patients with seroconfirmed measles, 17 patients (16%) had IgM-negative serology or rash illnesses that failed to meet the clinical case definition; their mean age (13 years), age at the time of vaccination, and time since vaccination did not differ from those of other vaccinated patients. The occurrence of secondary vaccine failure and vaccine-modified measles does not appear to be a major impediment to measles control in the United States but may lead to underreporting of measles cases and result in overestimation of vaccine efficacy in highly vaccinated populations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2278542

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  36 in total

1.  Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine.

Authors:  M Paunio; H Peltola; M Valle; I Davidkin; M Virtanen; O P Heinonen
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

2.  Healthcare Workers and Post-Elimination Era Measles: Lessons on Acquisition and Exposure Prevention.

Authors:  Shruti K Gohil; Sandra Okubo; Stephen Klish; Linda Dickey; Susan S Huang; Matthew Zahn
Journal:  Clin Infect Dis       Date:  2015-09-09       Impact factor: 9.079

3.  New York State's two-dose schedule for measles immunization.

Authors:  G S Birkhead; D L Morse; I J Mills; L F Novick
Journal:  Public Health Rep       Date:  1991 May-Jun       Impact factor: 2.792

4.  Characterization of a natural mutation in an antigenic site on the fusion protein of measles virus that is involved in neutralization.

Authors:  J Fayolle; B Verrier; R Buckland; T F Wild
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Molecular epidemiology and changing distribution of genotypes of measles virus field strains in Japan.

Authors:  Y Katayama; K Shibahara; T Kohama; M Homma; H Hotta
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

6.  Measles in Healthcare Facilities in the United States During the Postelimination Era, 2001-2014.

Authors:  Amy Parker Fiebelkorn; Susan B Redd; David T Kuhar
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

7.  Outbreak of measles among persons with secondary vaccine failure, China, 2018.

Authors:  Zhujiazi Zhang; Meng Chen; Rui Ma; Jingbin Pan; Luodan Suo; Li Lu
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

8.  Two independent outbreaks of measles in partially vaccinated junior high schools in Tottori, Japan.

Authors:  A Kawamoto; T Honda; K Ishida; T Ozeki; H Hayashibara; K Shiraki; S Hino
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 9.  Measles control in developing and developed countries: the case for a two-dose policy.

Authors:  T H Tulchinsky; G M Ginsberg; Y Abed; M T Angeles; C Akukwe; J Bonn
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

10.  Treating measles: the appropriateness of admission to a Wisconsin children's hospital.

Authors:  P L Havens; J C Butler; S E Day; B A Mohr; J P Davis; M J Chusid
Journal:  Am J Public Health       Date:  1993-03       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.